Since the vaccination plan began in Chile, more than 7.5 million people have completed two doses of the Coivd-19 vaccine and more than 9.3 million have received the first inoculation. In total, 16.9 million doses of this vaccine have been administered.
At the moment, the vaccination schedule continues its course, which has allowed vaccinating 61.4% of the target audience with the first dose and to 49.9% of the target audience with the second dose.
Chile’s vaccination plan has been considered successful and recognized by international entities such as the World Bank. Given this, doubts arise regarding the vaccines that are implemented in the country and what their differences are.
In Chile three vaccines are administered: BioNTech Laboratory Pfizer, Sinovac Laboratory CoronaVac Y Oxford of AstraZeneca laboratory. Here we explain the main differences between these vaccines.
Pfizer is a new generation vaccine and is developed with nucleic acid (RNA), which means that the genetic information of the virus is managed in it.
While the vaccine Sinovac is developed with inactivated virus. That is, the virus is inactivated by physical methods (heat) or chemicals and is then administered in the vaccine.
While, AstraZeneca is of the non-replicating viral vector type. These types of vaccines contain a manipulated viral version of another virus that works by triggering a reaction in the cells of the inoculated person, giving them instructions.
Regarding efficacy, the vaccine Pfizer has been shown to be 95% effective in the prevention of Covid-19 cases.
For its part, the Sinovac has demonstrated a 90.3% to prevent admission to ICU and 86% effectiveness to prevent death, 50% for cases with very mild symptoms, without the need for medical attention.
And the vaccine AstraZeneca is 79% effective against symptomatic cases and 100% effective against severe cases the critics. The data also shows an effectiveness of 8% for people over 65 years of age.
Regarding the type of people who can receive the vaccine, in Chile it was determined that Pfizer is licensed for individuals over the age of 16 and Sinovac for individuals over the age of 18. In both cases, the inoculation of pregnant women from 16 weeks of gestational age, with comorbidities, was authorized a few weeks ago.
On the other hand, the vaccine AstraZeneca is licensed for men over the age of 18 and women over the age of 55.
Regarding the required doses, Pfizer contemplates two inoculations, two weeks apart each. However, last month the CEO of the laboratory acknowledged that a third dose and an annual dose will probably be needed, as is the case with the flu vaccine.
The vaccine Sinovac also requires two doses, 14 days apart each.
For its part, AstraZeneca also requires two doses. However, the second dose can be given in a much longer time.